New hope for bile duct cancer: experimental drug targets tumors after chemotherapy fails
NCT ID NCT05297903
First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 25 times
Summary
This study tests an experimental drug called XmAb20717 in 27 adults with advanced bile duct cancer that worsened after or could not tolerate standard chemotherapy. The goal is to see if the drug can shrink tumors or slow cancer growth. Participants receive the drug alone, and researchers track how many respond and how long they live.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.